Compare Hut 8 Corp (HUT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs BIO-TECHNE Corp — how do they compare? Hut 8 Corp trades at $90 (market cap $10.56B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Hut 8 Corp and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.
| HUT | TECH | |
|---|---|---|
Market Cap | $10.56B | $11.24B |
Sector | Technology | Health |
52-Week High | $133.02 | $72.29 |
52-Week Low | $20.57 | $43.31 |
Enterprise Value | $17.99B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $88.59, down 2.27% today amid bearish technical signals and mixed quarterly earnings. The stock faces headwinds from negative net income margins and cash burn, but maintains strong analyst support with a 93.75% buy rating and a $165.11 consensus price target. Recent news highlights institutional accumulation and a strategic pivot to AI data centers, backed by a $26.6 billion contracted backlog.
Outlook hinges on execution of AI infrastructure projects, offering substantial upside if targets are met, but high valuation multiples and persistent losses pose risks. Investors must weigh growth potential against financial sustainability and market volatility.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
